Class Action Filed Against Sarepta Therapeutics, Inc. (SRPT) - August 25, 2025 Deadline to Join

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Sarepta Therapeutics, Inc. regarding a class action lawsuit related to misleading statements about the safety and efficacy of its gene therapy product, ELEVIDYS [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is from June 22, 2023, to June 24, 2025 [3]. - Allegations include that Sarepta Therapeutics made materially false and misleading statements about ELEVIDYS, which is a prescription gene therapy for Duchenne muscular dystrophy [3]. - Specific claims include that ELEVIDYS posed significant safety risks, trial protocols failed to detect severe side effects, and adverse events would lead to halted recruitment and increased regulatory scrutiny [3]. Group 2: Next Steps for Shareholders - Shareholders are encouraged to register for the class action by August 25, 2025, to participate in potential recovery [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case [4]. - There is no cost or obligation for shareholders to participate in the case [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights who have suffered due to deceit and illegal business practices [5]. - The firm is committed to ensuring companies adhere to responsible business practices and seeks recovery for investors affected by misleading statements [5].